Do PARP inhibitors have a role beyond mesothelioma in lung cancer?

Dean Fennell, University of Leicester, Leicester, UK, comments on the potential applicability of PARP inhibitors beyond classical indications beyond mesothelioma. Data from the PIN trial (NCT01788332) of olaparib maintenance in patients with advanced non-small cell lung cancer (NSCLC), showed promising results. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.